Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Rhea-AI Summary

Seer, a pioneering life sciences company focused on proteomics, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference in New York. The company's management team is set to engage in a fireside chat on Thursday, September 5th at 4:05 p.m. Eastern Time. This event presents an opportunity for investors and industry professionals to gain insights into Seer's innovative platform and business strategies.

Interested parties can access a live webcast of the session through the Investor section of Seer's website at investor.seer.bio. For those unable to attend in real-time, an archived replay will be made available on the company's website after the conference concludes. This participation underscores Seer's commitment to engaging with the investment community and showcasing its advancements in the proteomics field.

News Market Reaction

-0.62%

1 alert

-0.62% News Effect

On the day this news was published, SEER declined 0.62%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

REDWOOD CITY, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the company will be participating in the upcoming Morgan Stanley 22^nd Annual Global Healthcare Conference in New York, NY.

Seer’s management is scheduled to participate in a fireside chat on Thursday, September 5^th at 4:05 p.m. Eastern Time / 1:05 p.m. Pacific Time. A live webcast of the session will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the conference.

About Seer
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Investor Contact:
Carrie Mendivil
investor@seer.bio

Media Inquiries:
Patrick Schmidt
pr@seer.bio

FAQ

When is Seer (SEER) participating in the Morgan Stanley Healthcare Conference?

Seer (SEER) is participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5th, with a fireside chat scheduled for 4:05 p.m. Eastern Time / 1:05 p.m. Pacific Time.

How can I watch Seer's (SEER) presentation at the Morgan Stanley conference?

You can watch a live webcast of Seer's (SEER) fireside chat at the Morgan Stanley conference through the Investor section of Seer's website at investor.seer.bio. An archived replay will also be available on the website after the event.

What type of company is Seer (SEER)?

Seer (SEER) is a life sciences company that commercializes a disruptive new platform for proteomics, focusing on advancing the field of protein analysis and research.

Where is the Morgan Stanley Healthcare Conference that Seer (SEER) is attending taking place?

The Morgan Stanley 22nd Annual Global Healthcare Conference that Seer (SEER) is participating in is taking place in New York, NY.